SBI Securities’s Outlook Therapeutics OTLK Stock Holding History

SBI Securities’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$353	Hold	222	–	–	﹤0.01%	3155
2026 Q1	$46	Buy	222 +12	+6%	+$5	﹤0.01%	3594
2025 Q4	$332	Hold	210	–	–	﹤0.01%	3028
2025 Q3	$223	Hold	210	–	–	﹤0.01%	3278
2025 Q2	$336	Hold	210	–	–	﹤0.01%	3126
2025 Q1	$256	Hold	210	–	–	﹤0.01%	3131
2024 Q4	$397	Buy	+210	New	+$864	﹤0.01%	2980

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

SBI Securities's OTLK Position: Q2 2026 in Review

SBI Securities held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 222 shares worth $353. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

SBI Securities first reported a position in OTLK in Q4 2024 and has held it in 7 quarters since. The position peaked at $397 in Q4 2024. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

SBI Securities held 222 shares of Outlook Therapeutics worth $353 as of Q2 2026.
SBI Securities left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3155 holding.
SBI Securities first reported a position in Outlook Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Outlook Therapeutics position peaked at $397 in Q4 2024.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.